In this study, EBV-positive NPC patients showed that the vaccine could effectively induce the expansion of EBNA1- and LMP2-specific CD4+ and CD8+ cells in the peripheral blood lymphocytes of EBV-seropositive patients. Here, CD8A is linked to nasopharyngeal carcinoma.